Organ Transplant · Chapter 5
Antidepressants in the Transplant Recipient
The class you’ll reach for most — and the good news of the whole course: on a modern regimen, the workhorse antidepressants don’t touch the calcineurin inhibitor. Here’s the clean lane, the agents to watch, and the two to avoid.
Bottom Line Up Front
The 30-second version
- Most antidepressants are safe here — the ones you’d choose first don’t move the trough. Sertraline, escitalopram, citalopram, and mirtazapine are the guideline first-line, with negligible CYP3A4 effect on the calcineurin inhibitor.
- Two to avoid. Nefazodone (strong CYP3A4 inhibitor and hepatotoxic) and fluvoxamine (moderate CYP3A4 plus potent CYP1A2). Skip both — cleaner options exist.
- The real agent-level hazards aren’t the trough. They’re QT (citalopram/escitalopram caps, compounded by tacrolimus and calcineurin-inhibitor electrolyte wasting), platelet inhibition and bleeding (especially with thrombocytopenia in liver disease), and hyponatremia.
- Undertreating is its own risk. Post-transplant depression drives nonadherence and carries markedly higher mortality — so treat it properly. The clean lane means interaction fear is no excuse to under-dose.
Why This Matters — and Why It’s Reassuring
Start with the reason. Depression is common after transplantation, and it isn’t benign: post-transplant depressive disorders are associated with graft dysfunction, poorer adherence, worse quality of life, and roughly a 65% higher mortality risk. The through-line from Chapter 1 holds — depression feeds the nonadherence that costs grafts. So the goal here is not to tiptoe around antidepressants out of interaction anxiety; it’s to treat depression adequately using agents that leave the immunosuppressant alone.
And that’s very doable, because the antidepressant landscape in transplant is mostly reassuring. The Academy of Consultation-Liaison Psychiatry’s best-practice guidance names escitalopram, sertraline, and mirtazapine as first-line — chosen precisely because they don’t meaningfully perturb CYP3A4, and so don’t move the calcineurin-inhibitor trough. The interaction engine you learned in Chapters 3 and 4 mostly doesn’t fire for the drugs you’ll actually pick.
The First-Line Lane
Short, evidence-based, and clean on the trough.
| Agent | Why it’s first-line | Watch |
|---|---|---|
| Sertraline | Negligible CYP3A4 effect; broad safety data in the medically ill (including post-MI); the workhorse | Mild CYP2D6 inhibition at high dose; GI upset; bleeding / hyponatremia (class effects) |
| Escitalopram | Favorable interaction profile, well tolerated; guideline first-line | Dose-dependent QT (cap in the elderly / electrolyte-depleted); hyponatremia |
| Citalopram | Minimal interactions; effective | QT dose cap — 40 mg, or 20 mg if >60, hepatic, or CYP2C19 poor metabolizer (see QT section) |
| Mirtazapine | No meaningful CYP effect on the CNI; sedating and appetite-stimulating — useful for post-transplant insomnia, nausea, and poor appetite | Weight gain (already a steroid issue), sedation |
Second-Line & Watch
Usable, but rarely the simplest first choice — each carries a specific caveat.
| Agent | The issue in transplant |
|---|---|
| Fluoxetine | Not a meaningful CYP3A4 raiser of the CNI (contrary to some older reviews) — but potent CYP2D6, a very long half-life, and QT, with many downstream interactions. Rarely the cleanest pick. |
| Paroxetine | CYP2D6, anticholinergic, and a short half-life with a brisk discontinuation syndrome — a suboptimal choice, though not a calcineurin problem. |
| Venlafaxine / desvenlafaxine | Dose-dependent hypertension — unhelpful in patients already hypertensive from calcineurin inhibitors and steroids; a minor CNI interaction via desmethylvenlafaxine is described. |
| Duloxetine | CYP1A2 + CYP2D6 substrate (its level rises with fluvoxamine); a hepatotoxicity caution that matters in liver recipients. |
| Bupropion | Doesn’t move the CNI and is useful for fatigue and apathy — but it lowers the seizure threshold and can worsen calcineurin-inhibitor CNS effects, so assess for immunosuppressant neurotoxicity before starting. Also a CYP2D6 inhibitor. |
| Trazodone | Not a CNI raiser, but it is a CYP3A4 substrate — its own level rises in the inhibitor-heavy transplant milieu (azoles, diltiazem), risking oversedation, orthostasis, and rarely priapism. Low-dose for sleep is common, but mind the accumulation. |
Avoid
| Avoid | Why |
|---|---|
| Nefazodone | Strong CYP3A4 inhibitor that raises calcineurin inhibitors toward toxicity and black-box hepatotoxic — essentially never appropriate, absolutely not in a liver recipient. |
| Fluvoxamine | Moderate CYP3A4 inhibitor (raises the trough) and potent CYP1A2 inhibitor — cleaner SSRIs exist. |
| TCAs | Cardiac conduction and QT effects, anticholinergic burden, and overdose lethality — avoid, especially in cardiac recipients (nortriptyline with level monitoring only if truly needed). |
| MAOIs | Serotonergic and sympathomimetic interaction danger (hypertensive crisis, serotonin syndrome) in a heavy-polypharmacy population — avoid. |
The QT Layer — Where Transplant Stacks the Deck
The sharpest agent-level hazard isn’t the trough — it’s the QT interval. Citalopram carries an FDA dose cap for dose-dependent QT prolongation: a maximum of 40 mg/day, dropping to 20 mg/day in patients over 60, those with hepatic impairment, CYP2C19 poor metabolizers, or those on a CYP2C19 inhibitor. Escitalopram shows the same dose-dependent effect and is commonly capped lower in the elderly (often 10 mg/day, less in CYP2C19 poor metabolizers).
Two transplant realities compound this. First, tacrolimus itself prolongs the QT interval, so a citalopram or escitalopram contribution adds on top. Second, calcineurin inhibitors waste magnesium and potassium — and hypomagnesemia and hypokalemia are independent QT amplifiers. The net effect is that a dose that’s benign in a healthy outpatient can be meaningfully arrhythmogenic in a hypomagnesemic tacrolimus patient. The practical moves: check and replete magnesium and potassium, respect the citalopram/escitalopram caps and their elderly/hepatic reductions, get a baseline ECG when other QT drugs or risk factors are present, and prefer sertraline when QT is the dominant concern.
Bleeding, Sodium & Serotonin
Beyond QT, three class effects deserve attention in this population. SSRIs and SNRIs inhibit platelet aggregation and raise bleeding risk — which matters peri-operatively, alongside anticoagulation, with steroid-related GI risk, and especially in liver recipients or candidates with thrombocytopenia, where it can tip the balance away from an SSRI or SNRI. They also cause hyponatremia and SIADH, more so in older patients and those on other sodium-lowering drugs — worth a baseline and follow-up sodium. And serotonin syndrome is a real risk given the serotonergic company transplant patients keep: fentanyl, tramadol, ondansetron, and linezolid all turn up in perioperative and supportive care.
Choosing an Agent
Default: sertraline or escitalopram
Clean on the trough, strong evidence, well tolerated. Add mirtazapine when insomnia, nausea, or poor appetite dominate; citalopram is fine within its QT cap.
Mind the QT stack
In a tacrolimus patient, replete magnesium and potassium, respect the citalopram/escitalopram caps, and lean toward sertraline if QT risk is high or the patient is elderly and electrolyte-depleted.
Second-line only with a reason
Bupropion for fatigue or apathy (after checking for calcineurin-inhibitor neurotoxicity), venlafaxine if blood pressure allows, duloxetine if not a liver recipient — each carries a specific caveat, none is a first reach.
Don’t use nefazodone or fluvoxamine
Strong and moderate CYP3A4 inhibitors that raise the trough (nefazodone is also hepatotoxic). Avoid TCAs and MAOIs. A clean alternative always exists.
Clinical Pearls
Pearls
- The drugs you’d pick first are clean. Sertraline, escitalopram, citalopram, mirtazapine — guideline first-line, negligible effect on the calcineurin-inhibitor trough.
- Treat the depression properly. Post-transplant depression drives nonadherence and ~65% higher mortality — interaction fear is not a reason to under-dose when the clean lane exists.
- QT is the real agent hazard, and transplant amplifies it. Tacrolimus prolongs QT and calcineurin inhibitors waste magnesium and potassium — respect the citalopram (40 / 20 mg) and escitalopram caps and replete electrolytes.
- Mirtazapine is a two-for-one. Clean on the trough and useful for the insomnia, nausea, and poor appetite that follow transplant.
- Nefazodone and fluvoxamine are the two to skip. Strong and moderate CYP3A4 inhibitors respectively; nefazodone is also hepatotoxic.
- Bupropion needs a neurotoxicity check first. It lowers the seizure threshold and can worsen calcineurin-inhibitor CNS effects — assess before starting.
- Watch platelets and sodium. SSRIs and SNRIs raise bleeding risk (mind thrombocytopenia and anticoagulation) and cause hyponatremia.
- Fluoxetine’s transplant problem isn’t the CNI. Its issues are potent CYP2D6, a long half-life, and QT — not meaningful trough elevation.
Red Flags — Stop and Reassess
Hold and look closer
- New QTc prolongation or an arrhythmia on citalopram or escitalopram in a tacrolimus patient — check magnesium and potassium, review the dose cap, and reassess the QT stack.
- Citalopram above 40 mg (or above 20 mg in an elderly, hepatic, or CYP2C19-poor-metabolizer patient) — it exceeds the FDA cap; reduce.
- Nefazodone or fluvoxamine started in a transplant recipient — CYP3A4 inhibitors that raise the trough (nefazodone hepatotoxic); switch to a clean SSRI.
- New bleeding, bruising, or a falling platelet count on an SSRI or SNRI, especially in a liver recipient or on anticoagulation — reassess the agent.
- Bupropion started without a neurotoxicity check in a calcineurin-inhibitor patient — seizure-threshold and additive CNS risk; reassess.
Patient Counseling Script
Plain-language script
“The good news is that the antidepressants we most want to use don’t interfere with your transplant medication, so we can treat your mood properly without putting your organ at risk — and treating it matters, because feeling well helps you stay on your transplant regimen. A couple of things we watch: some of these medicines can nudge your heart’s rhythm, especially if your magnesium or potassium is low, so we may check those and an ECG; and they can slightly increase bleeding or lower your sodium, so tell us about easy bruising or if you feel confused or unwell. And please don’t start any new medicine or herbal product — St John’s wort especially — without checking with us first.”
EMR / Documentation Template
References
- Academy of Consultation-Liaison Psychiatry. Best Practice Guidance: Evaluation and Treatment of Depression in Solid Organ Transplant Recipients. J Acad Consult Liaison Psychiatry. 2023. (First-line antidepressants: escitalopram, sertraline, mirtazapine; routine depression screening.)
- Treating Depression After Heart Transplantation. Palliative Care Network of Wisconsin Fast Fact. (Citalopram/escitalopram and sertraline preferred for minimal interactions; assess for calcineurin-inhibitor neurotoxicity before bupropion; avoid nefazodone and St John’s wort.)
- Citalopram (Celexa) Prescribing Information; FDA Drug Safety Communications, 2011–2012. (Dose-dependent QT prolongation; maximum 40 mg/day, 20 mg/day in patients >60 years, hepatic impairment, or CYP2C19 poor metabolizers; CYP2C19 PM Cmax +68% / AUC +107%.)
- Depression across organ failure — pharmacologic choices in transplant recipients. Psychiatr Times. 2026. (Prioritize escitalopram, sertraline, citalopram, mirtazapine; avoid fluvoxamine, TCAs, MAOIs; SSRI platelet inhibition; thrombocytopenia caution; ~65% higher mortality with post-transplant depression.)
- Prograf (tacrolimus) Prescribing Information. Astellas Pharma. (Tacrolimus prolongs the QT interval; calcineurin inhibitors cause hypomagnesemia and hypokalemia — additive QT risk.)
- Transplant immunosuppressants: common drug interactions. Pharmacy Times. (Sertraline and escitalopram the antidepressants of choice; fluoxetine and paroxetine potent CYP2D6 inhibitors; nefazodone and fluvoxamine as CYP3A4 concerns; grapefruit avoidance.)
- DeVane CL, et al. Comparative CYP3A4 inhibition by antidepressants in vivo. (Among sertraline, fluoxetine, venlafaxine, and nefazodone, only nefazodone produced significant CYP3A4 inhibition; fluoxetine did not meaningfully affect a CYP3A4 substrate.)
Last reviewed July 2026. Part of the Psychiatry Education Forum Academy; for clinician education — it supports, and does not replace, individual clinical judgment and current local protocols.
That’s the antidepressant lane. The rest of the class chapters are inside.
This free chapter covered the drug you reach for most. The dosing block continues with the classes where the calls get harder — antipsychotics on QT and steroids, and the mood stabilizers where carbamazepine is off the table.
Educational use only. Refer to the sources cited above and current prescribing information for clinical decisions. Psychiatry Education Forum and authors assume no liability for use of this material. This chapter discusses depression and mortality; if you or someone you know is in crisis, seek local emergency or crisis support.
Responses